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Overview: Current diagnostic criteria for TMA proposed by
the Blood andMarrow Transplant Clinical Trials Network and
the International Working Group have limitations because
the renal and hematologic ﬁndings are not speciﬁc for TMA
after HSCT, as noted retrospectively by Cho et al (Trans-
plantation 2010).
Methods: To prospectively assess the utility of current
diagnostic TMA criteria we enrolled 100 pediatric HSCT
patients at a single institution and evaluated clinical and
laboratory markers of TMA during the ﬁrst 100 days post-
HSCT (Table 1). Patients with a biopsy diagnosis of TMA or
signs of hemolytic microangiopathy were assigned to the
TMA group (n¼37), with remaining HSCT recipients grouped
as non-TMA controls (n¼63). The ﬁrst lactate dehydrogenase
(LDH) elevation was considered the start of TMA.
Results: 37% of patients were diagnosed with TMA at
a median of 32 days (17, 43) (interquartile range) after HSCT.
The ﬁrst LDH elevation was noted at a median of 14 days (10,
20) after HSCT. The appearance of schistocytes and drop in
haptoglobin lagged LDH by 10 (2, 21) and 13.5 (7,22) days ,
and was present in 95% and 89% patients with TMA,
respectively. Proteinuria was an early sign of renal injury,
detected 4 days (-7, 21) after LDH elevation in 73% of patients
with TMA, while acute kidney injury (AKI), deﬁned as
a doubling of serum creatinine on 2 consecutive measures,
occurred in 49% of patients with TMA 3 days (-8,16) after LDH
elevation.
LDH elevation, low haptoglobin, schistocytosis, and
number of platelet and red cell transfusions were signiﬁcant
clinical markers of TMA, manifesting over a 14 day
period after LDH elevation. Patients with TMA required
more antihypertensive medications and were more likely
to have AKI and proteinuria early in the TMA course.
Patients with TMA had a signiﬁcantly higher incidence of
respiratory failure, need for the intensive care unit, andTable 1
Patients w
Elevated LDH 37 (100%)
Number of platelet transfusions 13 (10.5, 2
Number of red cell transfusions 5 (3, 8) [0
Schistocytes 35 (95%)
Haptoglobin below normal 33 (89%)
AKI 18 (49%)
Proteinuria (30 mg/dL) 27 (73%)
Number of antihypertensive medications 4 (2, 5) [1
Data presented as n (%) or median (25th, 75th percentile) [range]a higher 100 daymortality (all<0.001) compared to the non-
TMA controls.
Conclusion: We prospectively determined that current
clinical consensus criteria delay TMA diagnosis by at least by
2weeks, potentially placing HSCT recipients at risk for higher
morbidity and mortality from irreversible tissue injury.
Additional AKI biomarkers are needed to promptly diagnose
TMA, even before proteinuria, increased creatinine and
hypertension can be clinically detected.
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Recent recommendations for children with neuroblas-
toma are to not proceed to autologous transplantation
(aHCT) unless a complete remission (CR) or a very good
partial remission (VGPR) has been achieved according to the
International Neuroblastoma Staging System Response
Evaluation Criteria. Because our anecdotal experience sug-
gested that patients in partial remission (PR) may beneﬁt, we
reviewed data from the University of North Carolina at
Chapel Hill for outcomes following aHCT in PR. Between
September 1988 and June 2012, 102 patients were newly
diagnosed, and 29 patients (22 males) at a median age of 4.1
years (range, 0.7-32.7 years) underwent aHCT at our insti-
tution between May 1995 and September 2012. At the time
of aHCT, 9 (31%) were in CR, 4 (13.8%) in VGPR, 15 (51.7%) in
PR, and 1 (3.4%) had a mixed response (MR) with then-
current response criteria. All received preparative regimens
including melphalan, carboplatin, and etoposide. Thirteen
(44.8%) received fractionated TBI as part of the conditioning
regimen on the CCG 3891protocol; 2 received tandem aHCT
on the COG ANBL 0532 protocol. Twenty-six (89.7%) received
peripheral blood stem cell grafts. Of these 29 patients, 13
(44.8%) remain alive at a median of 852 days (range, 103-
6339 days) including 5/9 (55.6%) transplanted in CR, 2/4
(50%) in VGPR, and 6/15 (40%) in PR. Of those in PR at aHCT, 6
remain alive at a median of 526 days (range, 103-2506 days)
and 9 died at a median of 404 days (range, 251-1043 days).
Disease status of 14 evaluable PR recipients at day 100
included 4 who achieved CR, 8 remaining in PR, and 2 with
progressive disease. Twelve of these 15 are known to have
received further therapy including local radiation, chimeric
antibody, retinoic acid, and chemotherapy. The 1-year overall
survival for those transplanted in PR was approximately 36%.
Thus, aHCT in PR may not only contribute to improving
survival for these high risk children but may also provide
a bridge to other therapies that continue to provide hope to
families.ith TMA (n¼37) HSCT controls (n¼63) p-value
31 (49%) 0.0001
0) [2, 89] 7 (3, 15) [1, 63] 0.002
, 48] 3 (2, 4) [0, 17] 0.0002
10 (16%) 0.0001
23/62 (37%) 0.0001
20 (32%) 0.048
31 (49%) 0.02
, 8] 2 (1, 3) [1, 5] 0.0001
